These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 17409802

  • 1. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Lilenbaum R, Rubin M, Samuel J, Boros L, Chidiac T, Seigel L, Dowlati A, Graham P, Beaumont J, Du H.
    J Thorac Oncol; 2007 Apr; 2(4):306-11. PubMed ID: 17409802
    [Abstract] [Full Text] [Related]

  • 2. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027).
    Hesketh PJ, Chansky K, Lau DH, Doroshow JH, Moinpour CM, Chapman RA, Goodwin JW, Gross HM, Crowley JJ, Gandara DR.
    J Thorac Oncol; 2006 Jul; 1(6):537-44. PubMed ID: 17409914
    [Abstract] [Full Text] [Related]

  • 3. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP, Fossella F.
    Cancer; 2005 Dec 15; 104(12):2766-74. PubMed ID: 16288485
    [Abstract] [Full Text] [Related]

  • 4. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
    Califano R, Griffiths R, Lorigan P, Ashcroft L, Taylor P, Burt P, Lee L, Chittalia A, Harris M, Faivre-Finn C, Thatcher N, Blackhall F.
    Lung Cancer; 2011 Sep 15; 73(3):338-44. PubMed ID: 21296449
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
    Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J.
    Chest; 2006 Apr 15; 129(4):1031-8. PubMed ID: 16608954
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
    Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M.
    J Clin Oncol; 2005 Nov 20; 23(33):8389-95. PubMed ID: 16293869
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial.
    Nelli F, Naso G, De Pasquale Ceratti A, Saltarelli R, Dauria G, Lugini A, Ferraldeschi R, Picone V, Moscetti L, Cortesi E.
    J Chemother; 2004 Aug 20; 16(4):392-9. PubMed ID: 15332716
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.
    Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose Y, Okamoto H, Yamamoto N, Yoshioka H, Minato K, Sawa T, Iwamoto Y, Saka H, Mizusawa J, Shibata T, Nakamura S, Ando M, Yokoyama A, Nakagawa K, Saijo N, Tamura T.
    J Clin Oncol; 2015 Feb 20; 33(6):575-81. PubMed ID: 25584004
    [Abstract] [Full Text] [Related]

  • 14. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
    Lai CL, Tsai CM, Chiu CH, Wang GS, Su WJ, Chen YM, Perng RP.
    Jpn J Clin Oncol; 2005 Dec 20; 35(12):700-6. PubMed ID: 16303792
    [Abstract] [Full Text] [Related]

  • 15. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
    Tibaldi C, Bernardini I, Chella A, Russo F, Vasile E, Malventi M, Falcone A.
    Clin Lung Cancer; 2006 May 20; 7(6):401-5. PubMed ID: 16800966
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
    Park SH, Choi SJ, Kyung SY, An CH, Lee SP, Park JW, Jeong SH, Cho EK, Shin DB, Hoon Lee J.
    Cancer; 2007 Feb 15; 109(4):732-40. PubMed ID: 17211861
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.